UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

Annals of oncology, 2014-06, Vol.25 (6), p.1128-1136

2014

Link zum Volltext

Verfügbarkeit prüfen

Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation

Familial cancer, 2019-01, Vol.18 (1), p.1-8

2019

Link zum Volltext

Verfügbarkeit prüfen

PALB2, a major susceptibility gene for breast cancer

Gynécologie, obstétrique, fertilité & sénologie, 2018-11, Vol.46 (10-11), p.701-705

2018

Link zum Volltext

Verfügbarkeit prüfen

Is there a genetic anticipation in breast and/or ovarian cancer families with the germline c.3481_3491del11 mutation?

Familial cancer, 2018, Vol.17 (1), p.5-14

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results

Annals of oncology, 2006-01, Vol.17 (1), p.85-92

2006

Link zum Volltext

Verfügbarkeit prüfen

Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics

Genetics in medicine, 2010-12, Vol.12 (12), p.801-807

2010

Link zum Volltext

Verfügbarkeit prüfen

French version of FACT-G: validation and comparison with other cancer-specific instruments

European journal of cancer (1990), 2004-10, Vol.40 (15), p.2243-2252

2004

Link zum Volltext

Verfügbarkeit prüfen

Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO)

Critical reviews in oncology/hematology, 2010-10, Vol.76 (1), p.71-78

2010

Link zum Volltext

Verfügbarkeit prüfen

Techniques and complications of non-genetic risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)

Gynécologie, obstétrique, fertilité & sénologie, 2022-02, Vol.50 (2), p.121-129

2022

Link zum Volltext

Verfügbarkeit prüfen

French women’s breast self-examination practices with time after undergoing BRCA1/2 genetic testing

Familial cancer, 2012-06, Vol.11 (2), p.269-278

2012

Link zum Volltext

Verfügbarkeit prüfen

Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials

Annals of oncology, 2006-01, Vol.17 (1), p.65-73

2006

Link zum Volltext

Verfügbarkeit prüfen

PALB2, gène majeur de susceptibilité au cancer du sein

Gynécologie Obstétrique Fertilité & Sénologie, 2018-11, Vol.46 (10-11), p.701-705

2018

Link zum Volltext

Verfügbarkeit prüfen

uPA/PAI-1, Oncotype DX™, MammaPrint® Valeurs pronostique et prédictive pour une utilité clinique dans la prise en charge du cancer du sein

Oncologie (Paris, France), 2014, Vol.16 (4), p.196-206

2014

Link zum Volltext

Verfügbarkeit prüfen

Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1 2 mutations

European journal of human genetics : EJHG, 2011-05, Vol.19 (5), p.500-506

2011

Link zum Volltext

Verfügbarkeit prüfen

Prise en charge des cancers du sein : le changement, c’est maintenant

Gynécologie Obstétrique Fertilité & Sénologie, 2017-01, Vol.45 (1), p.3-4

2017

Link zum Volltext

Verfügbarkeit prüfen

Mutation analysis of PALB2 gene in French breast cancer families

Breast cancer research and treatment, 2015-12, Vol.154 (3), p.463-471

2015

Link zum Volltext

Verfügbarkeit prüfen

Variation in the interaction between familial and reproductive factors on the risk of breast cancer according to age, menopausal status, and degree of familiality

International journal of epidemiology, 2000-04, Vol.29 (2), p.214-223

2000

Link zum Volltext

Verfügbarkeit prüfen

Comprendre le cancer du sein: guide d’information SOR SAVOIR PATIENT à destination des patientes et de leurs proches

Oncologie (Paris, France), 2007-09, Vol.9 (9), p.655-662

2007

Link zum Volltext

Verfügbarkeit prüfen

The effects of interaction between familial and reproductive factors on breast cancer risk: a combined analysis of seven case-control studies

British journal of cancer, 1998-05, Vol.77 (9), p.1525-1536

1998

Link zum Volltext

Verfügbarkeit prüfen

Modalités et morbidité des mastectomies de réduction de risque en dehors du risque avéré de prédisposition héréditaire : recommandations du Collège national des gynécologues et obstétriciens français (CNGOF)

Gynécologie Obstétrique Fertilité & Sénologie, 2022-02, Vol.50 (2), p.121-129

2022

Link zum Volltext

Verfügbarkeit prüfen

Cancers du sein » : Recommandations pour la pratique clinique de Saint-Paul-de-Vence

Oncologie (Paris, France), 2005-08, Vol.7 (5), p.342-379

2005

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer : relationships with toxicities

Cancer chemotherapy and pharmacology, 1995-01, Vol.37 (1-2), p.110-116

1995

Link zum Volltext

Verfügbarkeit prüfen

Place des inhibiteurs de l’aromatase dans le cancer du sein de la femme ménopausée, en situation adjuvante: les acquis et les incertitudes en 2005

Journal de gynécologie, obstétrique et biologie de la reproduction, 2006-06, Vol.35 (4), p.327-340

2006

Link zum Volltext

Verfügbarkeit prüfen

Techniques and complications of non-genetic risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)

Innovative Practice in Breast Health, 2024-03, Vol.1, p.100002, Article 100002

2024

Link zum Volltext

Verfügbarkeit prüfen

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

Breast cancer research : BCR, 2020-01, Vol.22 (1), p.8-8, Article 8

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 26

Suche als RSS-Feed

Aktive Filter

ThemaBreast Cancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(26)

Sprache

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation

PALB2, a major susceptibility gene for breast cancer

Is there a genetic anticipation in breast and/or ovarian cancer families with the germline c.3481_3491del11 mutation?

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results

Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics

French version of FACT-G: validation and comparison with other cancer-specific instruments

Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO)

Techniques and complications of non-genetic risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)

French women’s breast self-examination practices with time after undergoing BRCA1/2 genetic testing

Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials

PALB2, gène majeur de susceptibilité au cancer du sein

uPA/PAI-1, Oncotype DX™, MammaPrint® Valeurs pronostique et prédictive pour une utilité clinique dans la prise en charge du cancer du sein

Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1 2 mutations

Prise en charge des cancers du sein : le changement, c’est maintenant

Mutation analysis of PALB2 gene in French breast cancer families

Variation in the interaction between familial and reproductive factors on the risk of breast cancer according to age, menopausal status, and degree of familiality

Comprendre le cancer du sein: guide d’information SOR SAVOIR PATIENT à destination des patientes et de leurs proches

The effects of interaction between familial and reproductive factors on breast cancer risk: a combined analysis of seven case-control studies

Modalités et morbidité des mastectomies de réduction de risque en dehors du risque avéré de prédisposition héréditaire : recommandations du Collège national des gynécologues et obstétriciens français (CNGOF)

Cancers du sein » : Recommandations pour la pratique clinique de Saint-Paul-de-Vence

Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer : relationships with toxicities

Place des inhibiteurs de l’aromatase dans le cancer du sein de la femme ménopausée, en situation adjuvante: les acquis et les incertitudes en 2005

Techniques and complications of non-genetic risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

Aktive Filter

Suchergebnisse filtern